Industry News

Alkem Laboratories Ltd. reported robust performance for the second quarter ended 30 September 2025. The company recorded revenues of Rs. 40,010 million, up by 17.2 % year-on-year.

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration USFDA for Diroximel Fumarate delayed-release capsules, 231 mg.

Zydus Lifesciences Limited has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.

Amgen announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke

Novo Nordisk India and Emcure Pharma announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India.

Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025, showcasing strong growth across all major business segments.

Pfizer Inc. issued a firm response following a ruling by the Court of Chancery of the State of Delaware that denied Pfizers request for a temporary restraining order to block Metsera, Inc. from terminating its merger agreement and accepting a competing proposal from Novo Nordisk A/S.

AstraZeneca has reported a strong set of results for the first nine months and third quarter of 2025, highlighting double-digit revenue growth, rising earnings, and record progress in its late-stage pipeline.